The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Study Overview
=================
Brief Summary
-----------------
To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Detailed Description
-----------------
OBJECTIVE: To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction. METHOD: 40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Official Title
-----------------
The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Conditions
-----------------
Cerebral Infarction

Intervention / Treatment
-----------------
* Drug: Erigeron Injection
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged no younger than 18yrs attack within 72 hours NIHSS score in the 2-25 points Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae Signed the informed consents Exclusion Criteria: patients aged younger than 18yrs Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation Patients with severe cognitive impairment Refused to cooperate or been unable to cooperation for neurological disorders Cerebral hemorrhage or hemorrhagic cerebral infarction Unstable vital signs dued to massive cerebral infarction Patients with serious heart, liver and renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Erigeron Injection<br>Erigeron Injection, 30ml,qd,i.v., for 7 days | Drug: Erigeron Injection<br>* Erigeron Injection, 30ml, iv, qd, for 7days<br>|
| Placebo Comparator: placebo<br>normal saline, 500ml,i.v.,qd, for 7 days | Drug: placebo<br>* normal saline, 500ml,i.v.,qd, for 7 days<br>* Other names: normal saline, 500ml,i.v.,qd, for 7 days;|
| No Intervention: health volunteers<br>health volunteers, no drug to be given. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the serum level of VEGF,MMP-9 and EPC |  | 0-7days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| National Institute of Health of stroke scale |  | 0-7days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
promoting angiogenesis in multiple targets, herbal medicine, traditional chinese medicine, random clinical trial